...Recent advances, however, are changing this landscape. Indirect approaches targeting BET proteins, CDK7, Aurora kinases, glutamine metabolism, and synthetic lethal interactions have renewed interest in MYC-directed therapy. Simultaneously, the metabolic theory of cancer offers a complementary framework for understanding MYC. Rather than viewing MYC solely as a mutation that drives uncontrolled proliferation, it can be seen as a master regulator that rewires cellular metabolism toward glycolysis, glutamine addiction, mitochondrial remodeling, and anabolic growth. This perspective integrates MYC naturally into the Five-Axis Metabolic Trap, where metabolic pressure rather than mutation-specific inhibition becomes the central therapeutic strategy.....
...8MYC supports mitochondrial remodeling and stem-cell survival.
Potential adjunctive agents include:
doxycycline
ivermectin
EGCG
sulforaphane
curcumin
melatonin
resveratrol or pterostilbene....
....MYC promotes angiogenesis, inflammation, and immune suppression.
Potential supportive agents include:
propranolol
omega-3 fatty acids
curcumin
modified citrus pectin (selected settings)
Axis 5 – Immune Restoration
MYC suppresses antitumor immunity through PD-L1 induction and cytokine remodeling.
Supportive strategies may include:
vitamin D optimization
melatonin
regular exercise
restoration of gut microbial diversity
adequate sleep and circadian regulation
Rather than attempting to inhibit MYC directly, the Five-Axis approach seeks to exploit the metabolic dependencies that MYC creates, reducing the tumor’s ability to adapt and survive.....
MYC occupies a unique position in cancer biology. Rather than functioning as a single oncogenic switch, it acts as the master conductor of malignant growth, integrating signals from diverse pathways into a coordinated program of proliferation, metabolic reprogramming, protein synthesis, genomic instability, stemness, and immune evasion. Dysregulation of MYC contributes to the development and progression of the majority of human cancers, making it one of the most important oncogenes ever discovered.
Despite decades of research, MYC has remained an extraordinarily difficult therapeutic target. Nevertheless, advances in indirect MYC inhibition and synthetic lethal strategies are beginning to challenge the notion that MYC is “undruggable.” Equally important, understanding MYC through the lens of cancer metabolism highlights opportunities to exploit the very dependencies it creates. By combining standard therapies with rational metabolic interventions that target glycolysis, glutamine utilization, mitochondrial function, inflammation, and immune suppression, it may be possible to weaken the metabolic foundation upon which MYC-driven cancers depend. As our understanding of MYC continues to evolve, it is likely to remain at the center of both molecular oncology and metabolism-based therapeutic strategies.